Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Perry who wrote (578)	4/2/1997 8:04:00 PM
From: margie	of 6136

Agouron's home page, www.agouron.com has a list of the names of analysts that follow agouron. Look under Investor Relations, and keep opening. Here's the upgrade from Robert Leboyer, of Brown Brothers Harriman Brown Brothers Upgrades Agouron To Near-Term Buy From Hold Dow Jones Online News, Wednesday, April 02, 1997 at 18:28 NEW YORK -(Dow Jones)- A Brown Brothers Harriman analyst on Wednesday upgraded Agouron Pharmaceuticals Inc. in the near-term to buy from hold. Analyst Robert LeBoyer set a price target of $90 a share on the stock in the near-term. In the long-term, he continues to rate the company an outperform, with a price target of $110. Near-term is about six months, while long-term is around a year. The analyst took the action because the company's price has declined even as "its fundamentals improved," he said. The company is in the middle of a launch of an AIDS drug called Viracept. The stock closed Wednesday at $74, up $2, or 2.78%.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next